All News

Megan Dulohery Scrodin, MD, highlights Mayo Clinic's innovative COPD care model, emphasizing multidisciplinary collaboration and AI tools for improved patient outcomes.

Initiatives aim to reduce residents' high rates of depression and increase self-care skills.

Experts discuss breakthroughs in respiratory virus vaccines.

Elinzanetant shows promise as a new treatment for menopause-related vasomotor symptoms, offering rapid relief and a favorable safety profile.

New clinical trial results suggest G-CSF as a promising alternative for managing hot flashes in menopausal women, without the risks of traditional therapies.

Clear communication, personalized counseling, and supportive environments help address barriers, empower patients, and enhance outcomes.

Pharmacy students face emotional struggles but require resilience, shared support, and love to move forward.

Although long COVID remains a complex disease, pharmacists are critical team members for patient symptom validation, managing polypharmacy, and navigating therapy access.

Research highlights the impact of sleep disturbances and vasomotor symptoms (VMS) on HRQoL in women transitioning to menopausal period, emphasizing the need for effective management.

Research reveals varying impacts of GLP-1 receptor agonists on asthma risk, urging careful medication selection for patients with diabetes and respiratory issues.

Explore how pharmacists can better support indigenous and Hispanic women during menopause through culturally sensitive care and family involvement.

When administering T-cell–modifying therapies, infections during and after treatment are a serious and pertinent risk.

When treating vasomotor symptoms (VMS), 15- and 20-mg doses of estetrol (E4) did not significantly hinder postmenopausal women’s blood pressure, including those with cardiovascular risks.

Chronic graft-vs-host disease (cGVHD) is the leading cause of late, non-relapse mortality for patients who have undergone an allogeneic hematopoietic stem cell transplant. Axatilimab, which has durable responses and an attractive safety profile, offers a novel mechanism of action for the treatment for patients who have not succeeded with at least 2 prior lines of systemic therapy.

A digital therapeutic app enhances access to behavioral cough suppression therapy.

Community pharmacists are especially valuable amid lower interest and staff shortages.

Infectious disease experts provide the latest updates in RSV, pneumococcal disease, whooping cough, and multidrug-resistant tuberculosis.

New research reveals how menopausal hormone therapy impacts cognitive health in postmenopausal women, highlighting the importance of administration routes and estrogen types.

Overdoses remain alarmingly high despite new tools like OTC Naloxone, highlighting persistent barriers to care.

Experts outline innovative approaches to reduce inequities in diagnostic access and optimize patient outcomes.

James Chalmers, MBChB, PhD, discusses the ASPEN trial's findings on brensocatib's impact on lung structure and function in bronchiectasis patients.

A recent study reveals imlunestrant plus abemaciclib shows superior efficacy over fulvestrant plus abemaciclib in treating advanced ER+, HER2- breast cancer.

Megan Dulohery Scrodin, MD, discusses COPD management challenges and the need for accessible care and cost reduction.

As psychedelic medicines near approval, pharmacists will become essential guides in safety and education.

From embedded PrEP care to rapid outbreak response logistics, new models are showing how pharmacists can establish successful public health partnerships to enhance patient access and equity.

Elinzanetant was effective in women with low vasomotor symptom (VMS) burden and those with endocrine therapy-caused VMS.

Prior to the 2025 American Heart Association (AHA) Scientific Sessions Meeting, Craig J. Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPS (AQ-Cardiology), CACP, discusses two recent papers that are influencing practice within the cardiovascular space.